Mineralys Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thanks, everyone, for joining us here at Guggenheim's Healthcare Innovation Conference. I am here with Mineralys, so Jon Congleton, CEO of Mineralys, joining us. I am Seamus Fernandez, one of the Senior Biopharma Analysts here at Guggenheim. So John, we are just weeks away from lorundrostat's December 22 PDUFA date. Before we get into the regulatory and launch details, will you just give us a sense of where the company stands today? What are the most important things to get right over the next couple of months?
Yeah. No, Seamus, thank you. Thanks to Guggenheim team for the invite to the conference. Always very productive and enjoy obviously talking about what we are doing. On the heels of the American Heart Association, where I was this past weekend in Chicago, I get excited about, I think, the focus on hypertension, the focus, frankly, on progressively getting patients to goal, and even sometimes more aggressively, the enthusiasm that we are seeing building around aldosterone as a target and the ASIs.
For us, and we will get into it in more detail, but it is a matter of having all of the key vectors, if you will, so market access, the med ed and dissemination of information around aldosterone and ASIs, the sales team, which we said we have fully in place right now, and all of the back office brand marketing materials ready to roll so that, presuming we have positive news on the action date, we can quickly transition into getting lorundrostat into the hands of physicians and patients in 2027.
Great. Obviously, your commercial background has the company extremely well-prepared for the launch, but how are you thinking about the opportunity for lorundrostat and the ASI class, broadly speaking? It is a market dominated by generics, and there are different approaches that you could take to attacking the category.
Yeah. As you know, I started my career 40 years ago carrying the bag, selling in the hypertension space when all of these generics were branded. A lot of great innovations brought into the space at that time. But if we fast-forward to where we are now, we still have over half of the patients treated are not at goal. Goal progressively comes down. Back when I was a rep, it was 140. It's now 130. There's a lot of argumentation to get down below 120 to really confer the benefits that one would expect on outcomes, which is ultimately what this game's all about. I get asked a lot of questions, and I'm sure you'll ask, difference between baxdrostat and lorundrostat, and those are important distinctions, but I think fundamentally, that's not what this is about.
It's about the 20 million patients who are on two or more meds, cannot get to goal with what's currently available, and a lot of these patients have trialed multiple drugs or have added multiple drugs and are just getting incremental value and not getting aggressively to that goal. From my standpoint, as we think about the introduction of lorundrostat, it is frankly more about juxtaposing lorundrostat's profile to alpha blocker, beta blocker, calcium channel blocker, MRA, because that's where those 20 million patients really need value. Then once a physician is kind of bought into, yes, ASIs are probably where I need to go, then we can talk about some of the distinctions, where there are similarities, where there's differences with baxdrostat. But I think that's where the real opportunity is to really tap into this market.
Got it. There's a lot of, I guess, sort of distinctions as we look at just the growing acceptance of GLP-1s.
There is an impact of GLP-1s on blood pressure that can be seen. Does that have much of an impact on the market opportunity from your perspective, or is that just kind of an incremental tool for physicians at this point?
I think it's going to be a foundational tool, right? The data that we're seeing with the anti-obesity treatments, whether it's single G, double G, triple G, are going to be foundational and a core to the treatment of cardio-kidney metabolic, the CKM disease condition, but they're not the silver bullet, right? What we've seen to date is about a 5 millimeter mercury reduction in blood pressure, mostly across anti-obesity treatments, and frankly, historically, to bariatric, to diet, and exercise. There's certainly some that respond more than that, some that respond less than that. I don't know that it meaningfully cuts into the opportunity for lorundrostat. We've looked at our data and looked very deeply at response relative to BMI, because there's clearly a link, we think, between visceral adiposity and aldosterone and uncontrolled or resistant hypertension.
And frankly, independent of BMI, you're seeing really robust, clinically meaningful reductions with lorundrostat. I don't think one eliminates the need for the other. I could actually see them coexisting well as part of a broader CKM treatment paradigm. And we've had some of our KOLs opine that that's where they see this going, that you're going to need to target obesity with whatever treatment you want, but you also have to really focus on aldosterone as well.
Got it. When we look at just sort of the data itself and the sort of value add of the ASIs, let's obviously focus on lorundrostat- Right and the value add that it offers.
Just walk us through the data, and really, I think that kind of brings us to the label. What do you hope to see in the label for lorundrostat, and what are the opportunities for differentiation?
Yeah. It's interesting. Three, four years ago, in a dialogue with the agency, Eliza Thompson kind of positioned the label as it's a tool to inform prescribers in how to use the drug, fundamentally. If you think about hypertension in the hands or being treated by a primary care doctor, by a nephrologist, by a cardiologist, they're not just thinking about hypertension, right? There's comorbidities, and I think that's what informed our clinical development program going back four years ago. It's why we did two really distinct pivotal studies, Launch-HTN and Real World. Come as you are with whatever drugs you're on, add lorundrostat, and see the benefit you get. We know we saw a 19 millimeter absolute, 11.7 millimeter placebo adjusted in that real-world population. Primary care, that's who they're treating. Cardiologists, on the other hand, tend to really maximize the background treatments.
They follow AHA guidelines as far as treatments they pick. They're going with, for the most part, maximal dose, and so we did that study with the Cleveland Clinic where we took patients off the background meds, maximized an AHA background treatment, followed them for three weeks, and only randomized those that could not get to goal, so truly confirmed. That becomes a really distinct dataset for cardiologists. Then we did our Explore program, CKD, OSA, because again, we're seeing comorbidities of either CKD and/or OSA and/or obesity. The latter study, Explore-OSA, was not part of the label submission, but Explore-CKD was. Each of these three distinct studies, I think, are very informative to the constituents that treat uncontrolled and resistant hypertension. It's what we put into our data package. It's what we put into our label.
It'll be part of the dialogues with the agency as far as which pieces of each of the studies make it into the label. As I look at just kind of a base case assumption, Launch-HTN, I think, is the largest study with an ASI in uncontrolled and resistant hypertension. It shows really meaningful blood pressure reduction, shows a very clear safety profile, and that as a base case in the label, I think, is a strong hand for us to make argumentation for the use of lorundrostat, third line or later, broadly, and a competitive profile relative to baxdrostat specifically.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
